Diamyd Medical AB (publ) (DMYD-B) - Cash Flow Conversion Efficiency

Latest as of February 2026: -0.233x

Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has a cash flow conversion efficiency ratio of -0.233x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-39.51 Million ≈ $-4.25 Million USD) by net assets (Skr169.79 Million ≈ $18.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Diamyd Medical AB (publ) (DMYD-B) net asset quality to measure how much of total assets are equity-financed.

Diamyd Medical AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Diamyd Medical AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Diamyd Medical AB (publ) (DMYD-B) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Diamyd Medical AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Diamyd Medical AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
CTRL Group Limited Ordinary Shares NASDAQ:MCTR	-0.546x
GR.SOU.COP. LS-01 F:E9E	N/A
IntegraFin Holdings plc LSE:IHP	0.599x
E for L Aim Public Company Limited BK:EFORL	-0.012x
VentriPoint Diagnostics Ltd V:VPT	0.021x
Lung Hwa Electronics Co Ltd TW:2424	-0.057x
BSA Ltd AU:BSA	1.679x
Neurotech International Ltd AU:NTI	-0.007x

Annual Cash Flow Conversion Efficiency for Diamyd Medical AB (publ) (2010–2025)

The table below shows the annual cash flow conversion efficiency of Diamyd Medical AB (publ) from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Diamyd Medical AB (publ).

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr280.00 Million ≈ $30.13 Million	Skr-169.68 Million ≈ $-18.26 Million	-0.606x	+31.55%
2024-08-31	Skr145.92 Million ≈ $15.70 Million	Skr-129.18 Million ≈ $-13.90 Million	-0.885x	-35.15%
2023-08-31	Skr169.40 Million ≈ $18.23 Million	Skr-110.96 Million ≈ $-11.94 Million	-0.655x	-50.64%
2022-08-31	Skr214.38 Million ≈ $23.07 Million	Skr-93.22 Million ≈ $-10.03 Million	-0.435x	+24.82%
2021-08-31	Skr189.26 Million ≈ $20.37 Million	Skr-109.47 Million ≈ $-11.78 Million	-0.578x	-348.38%
2020-08-31	Skr72.49 Million ≈ $7.80 Million	Skr16.88 Million ≈ $1.82 Million	0.233x	+137.31%
2019-08-31	Skr62.78 Million ≈ $6.76 Million	Skr-39.19 Million ≈ $-4.22 Million	-0.624x	+35.41%
2018-08-31	Skr43.01 Million ≈ $4.63 Million	Skr-41.56 Million ≈ $-4.47 Million	-0.966x	-224.51%
2017-08-31	Skr86.67 Million ≈ $9.33 Million	Skr-25.81 Million ≈ $-2.78 Million	-0.298x	+50.91%
2016-08-31	Skr29.26 Million ≈ $3.15 Million	Skr-17.75 Million ≈ $-1.91 Million	-0.607x	-30.94%
2015-08-31	Skr39.52 Million ≈ $4.25 Million	Skr-18.31 Million ≈ $-1.97 Million	-0.463x	-22.60%
2014-08-31	Skr44.16 Million ≈ $4.75 Million	Skr-16.69 Million ≈ $-1.80 Million	-0.378x	-66.13%
2013-08-31	Skr60.29 Million ≈ $6.49 Million	Skr-13.71 Million ≈ $-1.48 Million	-0.227x	-66.41%
2012-08-31	Skr409.58 Million ≈ $44.08 Million	Skr-55.99 Million ≈ $-6.03 Million	-0.137x	+32.98%
2011-08-31	Skr460.97 Million ≈ $49.61 Million	Skr-94.03 Million ≈ $-10.12 Million	-0.204x	-128.44%
2010-08-31	Skr314.78 Million ≈ $33.88 Million	Skr225.77 Million ≈ $24.30 Million	0.717x	--

About Diamyd Medical AB (publ)

ST:DMYD-B Sweden Biotechnology

Market Cap

$14.94 Million

Skr138.82 Million SEK

Market Cap Rank

#25971 Global

#539 in Sweden

Share Price

Skr1.04

Change (1 day)

+0.58%

52-Week Range

Skr1.01 - Skr17.62

All Time High

Skr71.00